ZTALMY

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania.

Active ingredients

The drug ZTALMY contains one active pharmaceutical ingredient (API):

1	Ganaxolone UNII 98WI44OHIQ - GANAXOLONE
	Ganaxolone is a methyl analogue of the endogenous neurosteroid allopregnanolone. Ganaxolone is a neuroactive steroid that positively and allosterically modulates gamma-aminobutyric acid type A (GABAA) receptors in the CNS by interacting with a recognition site that is distinct from other allosteric GABAA receptor modulators. Its anticonvulsant effects are thought to result from this modulation of GABAA receptor function providing constant, or tonic, modulation of GABA-mediated inhibitory neurotransmission.
	Read more about Ganaxolone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZTALMY Oral suspension	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AX27		N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3041200, 3041211
FR	Base de données publique des médicaments	60294720
IT	Agenzia del Farmaco	050778012, 050778024
LT	Valstybinė vaistų kontrolės tarnyba	1097536, 1097537
US	FDA, National Drug Code	81583-100